NQNoé Quittot

Noé Quittot

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Noé Quittot has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Bradley T. Hyman

    Massachusetts General Hospital, Department of Neurology, Boston, MA, USA

    2 shared publications
  • Aaron Held

    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

    1 shared publication
  • Alexandra Melloni

    Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

    1 shared publication
  • Aloysius Domingo

    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

    1 shared publication
  • Anastasie Mate de Gerando

    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA

    1 shared publication
  • Anne E. Wiedmer

    Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

    1 shared publication

Latest Publications

  • Open Access

    Tau isoform imbalance and aggregation are pathological hallmarks of X-linked dystonia-parkinsonism

    by Charles Jourdan Reyes, Aloysius Domingo, Ellen B. Penney, Ean Norenberg, Justin Han, Micaela G. Murcar, Christine A. Vaine, Nicolas A. Bravo-Vasquez, Hoang-Dai Tran, Noé Quittot, et al.

    SUMMARY: Tauopathies encompass diverse neurodegenerative diseases unified by aberrant patterns of tau deposition in brain. Although most appear sporadic, some are linked to genetic etiologies that offer unique mechanistic insights. Here we report that X-linked Dystonia-Parkinsonism (XDP), caused by a non-coding retrotransposon-associated repeat insertion in TAF1 , involves a significant imbalance of tau isoforms and the accumulation of hyperphosphorylated, four-repeat tau in the brain. In striatal tissue, both misfolded tau accumulation, predominantly in astrocytes, and MAPT exon 10 inclusion correlated with repeat length within the causal insertion. Transcriptomic profiling across brain regions revealed dysregulation of known tau-related pathways. Levels of phosphorylated tau181, glial fibrillary acidic protein, and neurofilament light chain were elevated in patient plasma and discriminated XDP from controls. These findings implicate defective tau proteostasis as a key pathogenic mechanism and position XDP as a genetic model for uncovering cellular drivers that may disrupt tau in other more common neurodegenerative diseases.


  • Open Access

    The ligand preference of LRP1 is regulated by O-glycans

    by John Hintze, Asli B. Topaktas, Thomas D. Madsen, Shifa Jebari-Benslaiman, Bethany H. Claridge, Silvia D’ANdrea, Noortje de Haan, Lasse H. Hansen, Rob Baars, Noé Quittot, et al.

    The family of low-density lipoprotein receptor (LDLR) and LDLR-related proteins (LRPs) are endocytic receptors serving as essential regulators of multiple physiological processes including cholesterol clearance, protein reabsorption, and neuronal protein trafficking. Site-specific O-glycans modify linkers of the ligand-binding domains of LRPs. Most linker O-glycans are initiated exclusively by GALNT11, 1 of 20 polypeptide GalNAc-transferase isoenzymes. Here, we investigate the role of GALNT11 linker O-glycans in the large and widely expressed multiligand receptor LRP1. In cell models expressing LRP1 with and without GALNT11, we demonstrate that while the uptake of certain ligands such as RAP and ApoE was unaffected, uptake of neurotoxic tau and amyloid-β was altered and in opposite directions. Characterization of LRP1 linker O-glycans indicated incomplete sialic acid capping, a feature that, in MD simulations, enabled inter- and intramolecular interactions. Our findings highlight a potential regulatory mechanism of endocytic receptors and identify the ligand repertoire of LRP1 as influenced by O-glycans, with implications for neurodegenerative disease.


  • Open Access

    Rare bioactive diffusible tau species from Alzheimer brain support both templated misfolding and fibril formation

    by Noé Quittot, Dhanush Sivasankaran, Dorothea Böken, Yu Chen, Joshua E. Chun, Anne E. Wiedmer, Victoria Derosla, Mariana B. M. S. Martins, Forest A. Brooks, Georg Meisl, et al.

    In Alzheimer’s disease, both classical neurofibrillary tangles, and diffusible, aqueous soluble (High Molecular Weight, or HMW) species are able to support templated misfolding. How these tau proteoforms relate is uncertain. Using sequential size exclusion and anion exchange chromatography, we fractionated the HMW tau population and found both seed competent, and seed not competent proteoforms. Super resolution, atomic force, and immunogold electron microscopy confirmed that the size and conformation of both bioactive and non-bioactive tau proteoforms are similar, with dimers, trimers, and tetramers predominating. The presence of surface phosphorylation correlates with seeding capacity. Bioactive tau at fMol concentrations can induce seeding in a reporter cell. The soluble bioactive species support aggregation of a truncated repeat domain tau construct into thioflavin T positive fibrils and retain seeding activity over serial amplification in vitro and in cellulo, whereas non-bioactive oligomeric species do not. Together, these findings indicate that oligomeric assembly is required but not sufficient for seeding; instead, specific biochemical attributes of a rare oligomeric tau subset confer self-propagating, prion-like templated misfolding.